Abstract
Background: The oral administration of Astaxanthin may decrease depression symptoms and improved cognitive function through its beneficial effects on inflammation, and oxidative stress. Objective: This study was designed to assess whether Astaxanthin supplementation can reduce symptoms of depression and increase MMSE score in patients with Type 2 Diabetes Mellitus. Methods: This randomized, double-blind, placebo-controlled clinical trial was performed in 44 patients between 30 and 60 y of age with a diagnosis of type 2 diabetes. Patients were randomly assigned to receive either a single capsule of 8 mg of Astaxanthin /day (n = 22) or placebo (n = 22) for 8 wk. The primary [Beck Depression Inventory (BDI), which examines depressive symptoms] and secondary (Mini-Mental State Examination (MSSE) score, which evaluates cognitive function) outcomes were assessed. Results: After 8 week of intervention, Mini-Mental State Examination baseline score was significantly improved only in the group treated with Astaxanthin, during study (p < 0.01). But no significant reduction in the Beck Depression Inventory (BDI) was observed in both group. Conclusion: Overall, Astaxanthin supplementation of patients with diabetes for 8 weeks had beneficial effects on the MMSE score. Key words: Astaxanthin, Cognitive function Depression
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
